Log in to save to my catalogue

Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic C...

Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic C...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_liu_182926

Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study

About this item

Full title

Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study

Publisher

United States: BMJ Publishing Group Ltd

Journal title

International journal of gynecological cancer, 2022-06, Vol.32 (6), p.761-768

Language

English

Formats

Publication information

Publisher

United States: BMJ Publishing Group Ltd

More information

Scope and Contents

Contents

ObjectiveThe Gynecologic Cancer InterGroup (GCIG)-Symptom Benefit Study was designed to evaluate the effects of chemotherapy on symptoms and health-related quality of life (HRQL) in women having chemotherapy for platinum resistant/refractory recurrent ovarian cancer (PRR-ROC) and potentially platinum sensitive with ≥3 lines of chemotherapy (PPS-ROC...

Alternative Titles

Full title

Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_DiVA_org_liu_182926

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_liu_182926

Other Identifiers

ISSN

1048-891X,1525-1438

E-ISSN

1525-1438

DOI

10.1136/ijgc-2021-003142

How to access this item